



**MICROBIA**

*A systems-based approach to  
drug discovery & biomanufacturing*

**FOR IMMEDIATE RELEASE**

**CONTACT:**  
Susan Brady  
Corporate Communications  
Microbia, Inc.  
617|621-8304  
sbrady@microbia.com

## **MICROBIA ANNOUNCES SUCCESSFUL DEVELOPMENT OF ADVANCED BIOMANUFACTURING PROCESS FOR TEVA PHARMACEUTICALS**

—Microbia's Precision Engineering™ Delivers  
Improved Pharmaceutical Manufacturing Efficiencies—

*CAMBRIDGE, Mass., October 27, 2003*— Microbia, Inc. today announced that it has successfully applied its Precision Engineering™ technology to improve the production efficiency of a key manufacturing process. The advance resulted from a collaboration Microbia initiated with Teva Pharmaceutical Industries Ltd. in September 2002 to develop improved, higher-yielding biomanufacturing processes using Microbia's Precision Engineering™ technology. Teva has validated the enhanced productivity of the resulting microbial fermentation in its manufacturing facility and plans to use the new bioprocess in commercial production. This represents the first commercial manufacturing use of Microbia's Precision Engineering™ technology and triggers a series of undisclosed payments from Teva to Microbia.

Precision Engineering™ is a comprehensive, systems-based approach to engineering the regulatory circuitry of microbes used in industrial-scale production of pharmaceuticals and fine chemicals. Benefits of Precision Engineering™ include reduced process-improvement cycle time and the ability to increase production without having to expand biomanufacturing facilities.

“We are very pleased that our Precision Engineering™ technology has been validated at commercial scale and has created tangible value for our partner, Teva” said Peter Hecht, CEO of Microbia. “Our Precision Engineering™ business is clearly gaining momentum, with partnerships spanning pharmaceuticals and fine chemicals.”

**MICROBIA** ([www.microbia.com](http://www.microbia.com)) is a privately held biotechnology company using a systems-based approach to making breakthrough drugs and biomanufacturing processes. The Company is pursuing development of novel anti-infectives and products for other human therapeutic indications, and is applying Precision Engineering™ to improve biomanufacturing efficiencies for collaborators in the pharmaceutical and chemical industries. Microbia has raised \$59 million in private equity financing and is located in Cambridge, Mass.

**TEVA PHARMACEUTICAL INDUSTRIES LTD.**, headquartered in Israel, is among the top 30 pharmaceutical companies in the world. The company develops, manufactures, and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. Close to 90 percent of Teva's sales are in North America and Europe.

Microbia, Inc.  
320 Bent Street Cambridge, MA 02141  
617 | 621-7722 Fax 617 | 494-0908 [microbia.com](http://microbia.com)

###